obesity drug news today glp-1 october 2025 Weight-Loss Demonstration Begins July 2026 GLP-1 therapies are changing obesity

There are also free Cognitive Behavioural Therapy for Insomnia (CBT-I) programs people can do at home to make sleep a priority. Report cessation effects to the TGA Given GLP-1 agonist cessation is an emerging area, pharmacists should consider reporting any effects to the TGA, or encourage patients to self-report

These innovations aim to offer more potent and durable clinical outcomes, improve patient responsiveness and address the growing need for advanced therapies within the global obesity landscape

Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans

Case series 1: Under medical oversight, two individuals with Bardet-Biedl syndrome and type 2 diabetes mellitus lost 15% of their total body weight in a 3- and 5-month period, respectively, following a combination therapy of tirzepatide and setmelanotide

How Much Weight Can You Expect to Lose with a GLP-1 program